Skip to Content
  • Previous Rank11
  • Revenues ($M)$208,357
  • Revenue Percent Change4.9%
  • Profits ($M)$67
  • Profits Percent Change-98.7%
  • Assets ($M)$60,381.00
  • Employees68,000

America’s largest pharmaceutical distributor slips two spots on the Global 500 this year, but the continued strength of its distribution business—serving as the middleman between manufacturers and pharmacies—lifted revenues 4.9%. The acquisition of Rexall Health powered some of that growth as did trends like the nation’s climbing drug prices and rising drug utilization rates. McKesson also moved ahead with its plan to divest its technology businesses in deals with Change Healthcare and Allscripts. The company, along with the country’s other large drug distributors, remains a target of litigation over its alleged role in the nation’s opioid epidemic.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Information

John H. Hammergren
Wholesalers: Health Care
HQ Location
San Francisco
Years on Global 500 List24
Figures are for fiscal year ended March 31, 2018.

McKesson Rank History

Key Financials (Last Fiscal Year)

($ Millions)% change
Revenues ($M)$208,3574.9%
Profits ($M)$67-98.7%
Assets ($M)$60,381.00-
Total Stockholder Equity ($M)$9,804.00-

Profit Ratios

Profit as % of Revenues-
Profits as % of Assets0.1%
Profits as % of Stockholder Equity0.7%